Effects of geldanamycin and thalidomide on the Th1/Th2 cytokine balance in mice subjected to operative trauma

Surgery

Volumn 141, Issue 4, 2007, Pages 490-500

  Nakano, Takumi ^a   Araki, Keijiro ^a   Nakatani, Hajime ^a   Kobayashi, Michiya ^a   Sugimoto, Takeki ^a   Furuya, Yasuo ^a   Matsuoka, Takanori ^a   Jin, Toufeng ^a   Hanazaki, Kazuhiro ^a  

^a KOCHI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GELDANAMYCIN; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MESSENGER RNA; MIFEPRISTONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; IMMUNE DEFICIENCY; IMMUNOMODULATION; LAPAROTOMY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; SURGICAL INJURY; TH1 CELL; TH2 CELL; UPREGULATION;

ANIMALS; BENZOQUINONES; CYSTEINE PROTEINASE INHIBITORS; CYTOKINES; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; LACTAMS, MACROCYCLIC; MALE; MICE; MICE, INBRED C57BL; SHOCK, SURGICAL; TH1 CELLS; TH2 CELLS; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33947327417     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2006.10.003     Document Type: Article

References (38)

1. Wood J.J., Rodrick M.L., O'Mahony J.B., et al. Inadequate interleukin 2 production: a fundamental immunological deficiency in patients with major burns. Ann Surg 200 (1984) 311-320
2. Horgan A.F., Mendez M.V., O'Riordain D.S., et al. Altered gene transcription after burn injury results in depressed T lymphocyte activation. Ann Surg 220 (1994) 342-352
3. O'Sullivan S.T., Lederer J.A., Horgan A.F., et al. Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann Surg 222 (1995) 482-492
4. Lyons A., Kelly J.L., Rodrick M.L., et al. Major injury increases production of interleukin-10 by cells of the immune system with a negative impact on resistance to infection. Ann Surg 226 (1997) 450-460
5. O'Riordain D.S., Mendez M.V., O'Riordain M.G., et al. Molecular mechanism of decreased interleukin-2 production after thermal injury. Surgery 114 (1993) 407-415
6. Lyons A., Goebel A., Mannick J.A., et al. Protective effects of early interleukin 10 antagonism on injury-induced immune dysfunction. Arch Surg 134 (1999) 1317-1324
7. Keith R.W., Walley N.W., Theodore J.S., et al. Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect Immun 64 (1996) 4733-4738
8. Song G.Y., Chung C.S., Chaudry I.H., et al. What is the role of interleukin 10 in polymicrobial sepsis: anti-inflammatory agent or immunosuppressant?. Surgery 126 (1999) 378-383
9. Faist E., Mewes A., Strasser T., et al. Alteration of monocyte function following major injury. Arch Surg 123 (1988) 287-292
10. Mack V.E., McCarter M.D., Naama H.A., et al. Dominance of T-helper 2-type cytokines after severe injury. Arch Surg 131 (1996) 1303-1309
11. De A.K., Kodys K.M., Pellegrini J., et al. Induction of global anergy rather than inhibitory Th2 lymphokines mediates post trauma T cell immunodepression. Clin Immunol 96 (2000) 52-66
12. Murphy T., Paterson H., Roger S., et al. Use of intracellular cytokine staining and bacterial superantigen to document suppression of the adaptive immune system in injured patients. Ann Surg 238 (2003) 401-411
13. Schäffer M., and Barbul A. Lymphocyte function in wound healing and following injury. Br J Surg 85 (1998) 444-460
14. Pratt W.B. The role of the hsp90-based chaperon system in signal transduction by nuclear receptors and receptors signaling via MAP-kinase. Annu Rev Pharmacol Toxicol 37 (1997) 297-326
15. Wax S., Piecyk M., Maritim B., et al. Geldanamycin inhibits the production of inflammatory cytokines in activated macrophages by reducing the stability and translation of cytokine transcripts. Arthritis Rheum 48 (2003) 541-550
16. Bucci M., Roviezzo F., Cicala C., et al. Geldanamycin, an inhibitor of heat shock protein 90 (Hsp90) mediated signal transduction has anti-inflammatory effects and interacts with glucocorticoid receptor in vivo. Br J Pharmacol 131 (2000) 13-16
17. Beck C.A., Estes P.A., Bona B.J., et al. The steroid antagonist RU486 exerts different effects on the glucocorticoid and progesterone receptors. Endocrinology 133 (1993) 728-740
18. Cronstein B.N., Kimmel S.C., Levin R.I., et al. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci USA 89 (1992) 9991-9995
19. Franks M.E., Macpherson G.R., and Figg W.D. Thalidomide. Lancet 363 (2004) 1802-1811
20. Kumar S, Witzig TE, Rajkumar V. Thalidomide: current role in the treatment of non-plasma cell malignancies. J Clin Oncol 22:2477-88.
21. Haslett P.A.J., Corral L.G., Albert M., et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187 (1998) 1885-1892
22. Davies F.E., Raje N., Hideshima T., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98 (2001) 210-216
23. Mokart D., Capo C., Blache J.L., et al. Early postoperative compensatory anti-inflammatory response syndrome is associated with septic complications after major surgical trauma in patients with cancer. Br J Surg 89 (2002) 1450-1456
24. Baigrie R.J., Lamont P.M., Kwiatkowski D., et al. Systemic cytokine response after major surgery. Br J Surg 79 (1992) 757-760
25. Zhang H., and Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 82 (2004) 488-499
26. Pratt W.B., Galigniana M.D., Harrell J.M., et al. Role of hsp90 and the hsp90-binding immunophilins in signaling protein movement. Cell Signal 16 (2004) 857-872
27. Pratt W.B., Silverstein A.M., and Galigniana M.D. A model for the cytoplasmic trafficking of signaling proteins involving the hsp90-binding immunophilins and p50cdc37. Topical review. Cell Signal 11; (1999) 839-851
28. Sampaio E.P., Sarno E.N., Galilly R., et al. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 173 (1991) 699-703
29. Kelly J.L., Lyons A., Soberg C.C., et al. Anti-interleukin-10 antibody restores burn-induced defects in T-cell function. Surgery 122 (1997) 146-152
30. Shneider C.P., Schwacha M.G., and Chaudry I.H. The role of interleukin-10 in the regulation of the systemic inflammatory response following trauma-hemorrhage. Biochim Biophys Acta 1689 (2004) 22-32
31. Pestka S., Krause C.D., Sarkar D., et al. Interleukin-10 and related cytokines and receptors. Ann Rev Immunol 22 (2004) 929-979
32. Fiorentino D.F., Bond M.W., and Mosmann T.R. Two types of mouse T helper cell: IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 170 (1989) 2081-2095
33. Biedermann T., Zimmermann S., Himmelrich H., et al. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat. Immunol 2 (2001) 1054-1060
34. Yao Y., Li W., Kaplan M.H., et al. Interleukin (IL)-4 inhibits IL-10 to promote IL-12 production by dendritic cells. J Exp Med 201 (2005) 1889-1903
35. Farivar A.S., Krishnadasan B., Naidu B.V., et al. Endogenous interleukin-4 and interleukin-10 regulate experimental lung ischemia reperfusion injury. Ann Thorac Surg 76 (2003) 253-259
36. Welborn III M.B., Moldawer L.L., Seeger J.M., et al. Role of endogenous interleukin-10 in local and distant organ injury after visceral ischemia-reperfusion. Shock 20 (2003) 35-40
37. Zimmerman M.A., Reznikov L.L., Raeburn C.D., et al. Interleukin-10 attenuates the response to vascular injury. J Surg Res 121 (2004) 206-213
38. Huse M., Lillemeier B.F., Kuhns M.S., et al. T cells use two directionally distinct pathways for cytokine secretion. Nat Immunol 7 (2006) 247-255